Digestive Diseases and Sciences

, Volume 58, Issue 3, pp 706–714 | Cite as

RETRACTED ARTICLE: Effect of miR-451 on the Biological Behavior of the Esophageal Carcinoma Cell Line EC9706

  • Tao Wang
  • Wen-qiao Zang
  • Min Li
  • Na Wang
  • Yu-ling ZhengEmail author
  • Guo-qiang ZhaoEmail author
Original Article



MicroRNAs play important roles in coordinating a variety of cellular processes. Abnormal expression of miRNAs has been linked to several cancers. However, the functional role of miR-451 in esophageal squamous cell carcinoma remains unclear.


The present study explored the effects of miR-451 on the biological behavior of the esophageal carcinoma cell line EC9706.


Synthetic miR-451 mimics were transfected into EC9706 cells using Lipofectamine™ 2000. The expression of miR-451 was analyzed by RT–PCR and the expressions of Bcl-2, AKT and phosphorylated AKT were analyzed by Western blotting. The MTT assay, soft agar colony formation assay, transwell assay and FACS were used to assess the effect of miR-451 on EC9706 cell proliferation, invasion, metastasis and apoptosis. Tumor growth was assessed by subcutaneous inoculation of cells into BALB/c nude mice.


In comparison to the controls, a significant increase in the expression of miR-451 was associated with significantly decreased expressions of Bcl-2, AKT and p-AKT, and a significant increase in the apoptosis rate. The number of cell clones was significantly decreased by miR-451 expression, which also caused the inhibition of cell proliferation. The average number of cells penetrating the matrigel was significantly lower than the controls. Injection of miR-451 inhibited tumor growth in a xenograft model.


Upregulated expression of miR-451 induced apoptosis and suppressed cell proliferation, invasion and metastasis in the esophageal carcinoma cell line EC9706. In addition, injection of miR-451 inhibited tumor growth in a xenograft model of esophageal cancer.


Esophageal neoplasms miR-451 Cell proliferation Apoptosis Neoplasm invasiveness 


Conflict of interest



  1. 1.
    Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science. 2005;309:1519–1524.CrossRefGoogle Scholar
  2. 2.
    Esteller M. Non coding RNAs in human disease. Nat Rev Genet. 2011;12:861–887.CrossRefGoogle Scholar
  3. 3.
    Van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNA binding proteins and its implications for cancer. Nat Rev Cancer. 2011;11:644–656.CrossRefGoogle Scholar
  4. 4.
    Kozomara A, Griffiths Jones S. miRBase: integrating microRNA annotation and deep sequencing data. Nucleic Acids Res. 2011;39:D152–D157.CrossRefGoogle Scholar
  5. 5.
    Tie J, Fan D. Big roles of microRNAs in tumorigenesis and tumor development. Histol Histopathol. 2011;26:1353–1361.PubMedGoogle Scholar
  6. 6.
    Cao XF, Li SQ. Role of miRNA in the diagnosis, prognosis and treatment of esophageal cancer. Zhonghua Zhong Liu Za Zhi. 2011;33:161–164.PubMedGoogle Scholar
  7. 7.
    Altuvia Y, Landgraf P, Lithwick G, et al. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res. 2005;33:2697–2706.CrossRefGoogle Scholar
  8. 8.
    Dela Cruz F, Matushansky I. MicroRNAs in chromosomal translocation associated solid tumors: learning from sarcomas. Discov Med. 2011;12:307–317.PubMedGoogle Scholar
  9. 9.
    Negrini M, Ferracin M, Sabbioni S, et al. MicroRNAs in human cancer: from research to therapy. J Cell Sci. 2007;120:1833–1840.CrossRefGoogle Scholar
  10. 10.
    Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–866.CrossRefGoogle Scholar
  11. 11.
    Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of mature mi-croRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT–PCR. Clin Chem. 2008;54:1696–1704.CrossRefGoogle Scholar
  12. 12.
    Hu X, Macdonald DM, Huettner PC, et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol. 2009;114:457–464.CrossRefGoogle Scholar
  13. 13.
    Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010;11:136–146.CrossRefGoogle Scholar
  14. 14.
    Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 2011;47:784–791.CrossRefGoogle Scholar
  15. 15.
    Takagi T, Iio A, Nakagawa Y, et al. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology. 2009;77:12–21.CrossRefGoogle Scholar
  16. 16.
    Bandres E, Bitarte N, Arias F, et al. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res. 2009;15:2281–2290.CrossRefGoogle Scholar
  17. 17.
    Bian HB, Pan X, Yang JS, et al. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res. 2011;30:20–30.CrossRefGoogle Scholar
  18. 18.
    Heinzelmann J, Henning B, Sanjmyatav J, et al. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol. 2011;29:367–373.CrossRefGoogle Scholar
  19. 19.
    Zhu H, Wu H, Liu X, et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76:582–588.CrossRefGoogle Scholar
  20. 20.
    Tian Y, Nan Y, Han L, et al. MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma. Int J Oncol. 2012;40:1105–1112.PubMedGoogle Scholar
  21. 21.
    Campani D, Esposito I, Boggi U, et al. Bcl-2 expression in pancreas development and pancreatic cancer progression. J Pathol. 2001;194:444–450.CrossRefGoogle Scholar
  22. 22.
    Martin AP, Park MA, Mitchell C, et al. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol. 2009;76:327–341.CrossRefGoogle Scholar
  23. 23.
    Azmi AS, Wang Z, Philip PA, et al. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs. 2010;16:59–70.CrossRefGoogle Scholar
  24. 24.
    Azmi AS, Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol. 2009;218:13–21.CrossRefGoogle Scholar
  25. 25.
    Regula KM, Ens K, Kirshenbaum LA. IKK beta is required for Bcl-2-mediated NF-kappa B activation in ventricular myocytes. J Biol Chem. 2002;277:38676–38682.CrossRefGoogle Scholar
  26. 26.
    Mortenson MM, Galante JG, Gilad O, et al. BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer. J Cell Biochem. 2007;102:1171–1179.CrossRefGoogle Scholar
  27. 27.
    Fahy BN, Schlieman MG, Mortenson MM, et al. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol. 2005;56:46–54.CrossRefGoogle Scholar
  28. 28.
    Kumar P, Ning Y, Polverini PJ. Endothelial cells expressing Bcl-2 promotes tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion. Lab Invest. 2008;88:740–749.CrossRefGoogle Scholar
  29. 29.
    Azmi AS, Philip PA, Zafar SF, et al. PAR-4 as a possible new target for pancreatic cancer therapy. Expert Opin Ther Targets. 2010;14:611–620.CrossRefGoogle Scholar
  30. 30.
    Yang ZZ, Tschopp O, Baudry A, et al. Physiological functions of protein kinase B/Akt. Biochem Soc Trans. 2004;32:350–354.CrossRefGoogle Scholar
  31. 31.
    Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9:59–71.CrossRefGoogle Scholar
  32. 32.
    Chen JY, Lin JR, Cimprich KA, Meyer T. A two-dimensional ERK-AKT signaling code for an NGF-triggered cell-fate decision. Mol Cell. 2012;45:196–209.CrossRefGoogle Scholar
  33. 33.
    Boehme KA, Kulikov R, Blattner C. p53 stabilization in response to DNA damage requires Akt/PKB and DNA–PK. Proc Nat Acad Sci USA. 2008;105:7785–7790.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of TumorThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouPeople’s Republic of China
  2. 2.Department of Hemato-TumorThe First Affiliated Hospital of Henan University of TCMZhengzhouPeople’s Republic of China
  3. 3.Department of Microbiology and Immunology, College of Basic Medical SciencesZhengzhou UniversityZhengzhouPeople’s Republic of China

Personalised recommendations